Sign inJoin waitlistJoin the waitlist

DM

Daniel Maslyar

Asst. Clinical Professor Vol · University of California (San Francisco) School of Medicine

Credentials: · ·

History

University of California (San Francisco) School of Medicine
Present

Hematology and Medical Oncology
Internal Medicine

Research

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind,…
The Lancet Oncology · 2017 · 399 citations
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts
Proceedings of the National Academy of Sciences of the United States of America · 2002 · 268 citations
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Clinical Cancer Research · 2019 · 256 citations

EH
Eric Humke
4 papers
Joyce Liu
3 papers
Kathleen Moore
3 papers
Michael Birrer
3 papers
AV
Anjali Vaze
2 papers
Ari Baron
2 papers
BF
Bernard Fine
2 papers
EH
Erika Hamilton
2 papers
HB
Howard Burris
2 papers
JI
Jeffrey Infante
2 papers
SI
Steven Isakoff
2 papers
AY
Alex Yeung
1 paper

Clinical trials

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Study director · Completed · Phase 1
Genentech, Inc.
2011–2020
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer
Study director · Completed · Phase 1
Genentech, Inc.
2011–2016